ALLO – Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc.ALLO
$1.13Name : Allogene Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $247,136,640.00
EPSttm : -1.32
Allogene Therapeutics, Inc.
$1.13
3.42%$0.04Float Short %
21.04
Margin Of Safety %
Put/Call OI Ratio
0.23
EPS Next Q Diff
0.01
EPS Last/This Y
0.12
EPS This/Next Y
-0.17
Price
1.12
Target Price
9.18
Analyst Recom
1.21
Performance Q
-19.29
Relative Volume
1.29
Beta
0.34
Ticker: ALLO
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-04-14 | ALLO | 1.43 | 0.24 | 0.18 | 6499 |
| 2025-04-15 | ALLO | 1.47 | 0.24 | 2.00 | 6501 |
| 2025-04-16 | ALLO | 1.405 | 0.25 | 999.99 | 6545 |
| 2025-04-17 | ALLO | 1.455 | 0.26 | 1.33 | 6596 |
| 2025-04-18 | ALLO | 1.45 | 0.26 | 0.59 | 6596 |
| 2025-04-21 | ALLO | 1.43 | 0.25 | 0.09 | 5653 |
| 2025-04-22 | ALLO | 1.585 | 0.24 | 0.08 | 5754 |
| 2025-04-23 | ALLO | 1.605 | 0.24 | 0.02 | 5933 |
| 2025-04-24 | ALLO | 1.565 | 0.22 | 0.67 | 6213 |
| 2025-04-25 | ALLO | 1.55 | 0.22371012209531 | 0.0076045627376426 | 6214 |
| 2025-04-28 | ALLO | 1.57 | 0.21855194929902 | 1.8571428571429 | 6345 |
| 2025-04-29 | ALLO | 1.54 | 0.23 | 0.03 | 6417 |
| 2025-04-30 | ALLO | 1.68 | 0.22 | 0.00 | 6682 |
| 2025-05-01 | ALLO | 1.685 | 0.22 | 0.00 | 6707 |
| 2025-05-02 | ALLO | 1.705 | 0.22 | 0.45 | 6704 |
| 2025-05-05 | ALLO | 1.615 | 0.22 | 0.32 | 6717 |
| 2025-05-06 | ALLO | 1.27 | 0.22 | 0.32 | 6749 |
| 2025-05-07 | ALLO | 1.195 | 0.23 | 1.76 | 6802 |
| 2025-05-08 | ALLO | 1.175 | 0.23 | 0.10 | 6857 |
| 2025-05-09 | ALLO | 1.15 | 0.23 | 0.01 | 6864 |
| 2025-05-12 | ALLO | 1.16 | 0.23 | 0.38 | 6924 |
| 2025-05-13 | ALLO | 1.13 | 0.23 | 0.07 | 6982 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-04-14 | ALLO | 1.43 | 29.0 | - | -1.12 |
| 2025-04-15 | ALLO | 1.46 | 29.0 | - | -1.12 |
| 2025-04-16 | ALLO | 1.40 | 29.0 | - | -1.12 |
| 2025-04-17 | ALLO | 1.45 | 29.0 | - | -1.12 |
| 2025-04-18 | ALLO | 1.45 | 29.0 | - | -1.20 |
| 2025-04-21 | ALLO | 1.42 | 19.1 | - | -1.20 |
| 2025-04-22 | ALLO | 1.59 | 19.1 | - | -1.20 |
| 2025-04-23 | ALLO | 1.61 | 19.1 | - | -1.20 |
| 2025-04-24 | ALLO | 1.57 | 19.1 | - | -1.20 |
| 2025-04-25 | ALLO | 1.55 | 19.1 | - | -1.20 |
| 2025-04-28 | ALLO | 1.57 | 20.0 | - | -1.20 |
| 2025-04-29 | ALLO | 1.54 | 20.0 | - | -1.20 |
| 2025-04-30 | ALLO | 1.68 | 20.0 | - | -1.20 |
| 2025-05-01 | ALLO | 1.69 | 20.0 | - | -1.20 |
| 2025-05-02 | ALLO | 1.70 | 20.0 | - | -1.20 |
| 2025-05-05 | ALLO | 1.62 | 20.0 | - | -1.20 |
| 2025-05-06 | ALLO | 1.27 | 20.0 | - | -1.20 |
| 2025-05-07 | ALLO | 1.20 | 20.0 | - | -1.20 |
| 2025-05-08 | ALLO | 1.17 | 20.0 | - | -1.20 |
| 2025-05-09 | ALLO | 1.16 | 20.0 | - | -1.20 |
| 2025-05-12 | ALLO | 1.17 | 20.0 | - | -1.20 |
| 2025-05-13 | ALLO | 1.12 | 22.4 | - | -1.20 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-04-14 | ALLO | -0.26 | -6.02 | 24.91 |
| 2025-04-15 | ALLO | -0.26 | -6.02 | 24.91 |
| 2025-04-16 | ALLO | -0.26 | -6.02 | 24.91 |
| 2025-04-17 | ALLO | -0.26 | -6.02 | 24.91 |
| 2025-04-18 | ALLO | -0.26 | -6.02 | 24.91 |
| 2025-04-21 | ALLO | -0.26 | -6.12 | 24.91 |
| 2025-04-22 | ALLO | -0.26 | -6.12 | 24.91 |
| 2025-04-23 | ALLO | -0.27 | -6.12 | 24.43 |
| 2025-04-24 | ALLO | -0.28 | -6.12 | 24.43 |
| 2025-04-25 | ALLO | -0.28 | -6.12 | 24.43 |
| 2025-04-28 | ALLO | -0.28 | -10.89 | 23.06 |
| 2025-04-29 | ALLO | -0.28 | -10.89 | 23.06 |
| 2025-04-30 | ALLO | -0.28 | -10.89 | 23.06 |
| 2025-05-01 | ALLO | -0.28 | -10.89 | 23.06 |
| 2025-05-02 | ALLO | -0.28 | -10.89 | 23.06 |
| 2025-05-05 | ALLO | -0.28 | -11.07 | 23.06 |
| 2025-05-06 | ALLO | -0.28 | -11.07 | 23.06 |
| 2025-05-07 | ALLO | -0.28 | -11.07 | 22.91 |
| 2025-05-08 | ALLO | -0.28 | -11.07 | 22.91 |
| 2025-05-09 | ALLO | -0.28 | -11.07 | 22.91 |
| 2025-05-12 | ALLO | -0.28 | -6.39 | 21.04 |
| 2025-05-13 | ALLO | -0.28 | -6.39 | 21.04 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.28
Avg. EPS Est. Current Quarter
-0.28
Avg. EPS Est. Next Quarter
-0.27
Insider Transactions
-0.28
Institutional Transactions
-6.39
Beta
0.34
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
23
Growth Score
27
Sentiment Score
2
Actual DrawDown %
98
Max Drawdown 5-Year %
-97.9
Target Price
9.18
P/E
Forward P/E
PEG
P/S
12357.08
P/B
0.57
P/Free Cash Flow
EPS
-1.34
Average EPS Est. Cur. Y
-1.2
EPS Next Y. (Est.)
-1.37
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
1.29
Return on Equity vs Sector %
-84.7
Return on Equity vs Industry %
-67.8
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.08
EBIT Estimation
Allogene Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 226
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
stock quote shares ALLO – Allogene Therapeutics, Inc. Stock Price stock today
news today ALLO – Allogene Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALLO – Allogene Therapeutics, Inc. yahoo finance google finance
stock history ALLO – Allogene Therapeutics, Inc. invest stock market
stock prices ALLO premarket after hours
ticker ALLO fair value insiders trading